Biocon received Health Canada approval for its Yesintek autoinjector. This new format offers patients a convenient treatment option for psoriasis. The autoinjector is also indicated for psoriatic arthritis and Crohn's disease. This approval strengthens Biocon's immunology product portfolio in Canada. The company aims to increase patient access to affordable medicines globally.